news
Next-generation therapeutic helps immune cells detect, destroy cancer
Researchers have found that cancer cells evade destruction by macrophages in two ways...
List view / Grid view
Immuno-oncology therapeutics
article
Lymphocytes armed to kill: how customised cell engineering advances immunotherapy
The immune system is now regarded as a powerful weapon in the war against cancer, and in the current era immune cells have become ‘living drugs’. This review article considers some of the key advances in immuno-oncology...
news
Researchers identify compound to prevent breast cancer cells from activating in brain
Researchers have used computer modelling to find an existing investigational drug compound for leukaemia patients to treat triple negative breast cancer...
article
Drug Target Review – Issue #1 2018
In this issue: how customised cell engineering advances immunotherapy, how insights into auto-immunity are providing new opportunities for immune-oncology, and advances in lab automation and robotics are accelerating the pace of antimicrobial therapy.
news
Immune cells dictate tumour progression
Analysing individuals' genotypes and immunotypes could yield customised treatments for prostate cancer...
news
BTSA1 causes cancer to self-destruct without affecting healthy cells
Scientists have discovered a compound that causes cancer cells to self-destruct while sparing healthy cells...
webinar
Advancing the discovery of immunotherapeutics with large scale multiplexed experiments
27 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the challenges faced with antibody screening and how the iQue Screener can give an evaluation of cell killing mechanism, screening for immune checkpoint inhibitors and more...
webinar
Evaluating immunotherapeutic approaches with large scale functional assays for immuno-oncology
22 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the need for robust high content tools for current immunotherapeutic approaches, and how IntelliCyt's iQue Screener PLUS can give functional efficacy of immuno-oncology therapies...
news
Immune cells the missing ingredient in new bladder cancer treatment
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer...
news
Cancer Research UK sets out latest £20m grand challenges
Cancer Research UK has launched the second phase of its global Grand Challenge by announcing eight new questions – identified as some of the biggest barriers to making progress against cancer – and inviting the world’s top scientists to come together with new proposals to tackle them.
news
Numab and Kaken enter into an antibody collaboration
Numab Therapeutics announced a collaboration and option agreement with Kaken Pharmaceutical for the identification of a multispecific antibody candidate for development in inflammatory disease.
article
Antibodies In-Depth Focus 2017
Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy...
news
£100 million for Cancer Research’s ‘grand challenge’ competition winners
Cancer Research UK announced that four international teams are the first recipients of its global £100m Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.
news
Macrophage raises £9 million & acquires immune-oncology technology
Macrophage Pharma, a newly formed immune-oncology company, has successfully raised £9 million in a Series A equity financing round.
news
Rignotec raises €15 million to advance RIG-I targeted immuno-oncology therapeutics
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The funding will advance the ongoing development of Rigontec’s RIG-I agonist platform targeting oncological, anti-infective and inflammatory indications as well as accelerate the progress of lead candidate RGT100 towards the clinic...